Department of Pharmaceutics, School of Pharmaceutical Science, Shenyang Pharmaceutical University, No 103, Wenhua Road, Shenyang 110016, China.
Pharm Res. 2013 Jan;30(1):269-79. doi: 10.1007/s11095-012-0871-9. Epub 2012 Sep 14.
To make a comparative study on sustained delivery performance of rhIFN with random amorphous and spherical crystal-like ordered self-assemblies.
The rhIFN self-assemblies were identified in batch crystallization mode. Physico-chemical characteristics were compared, including morphology, XRD, FTIR, CD, biological potency, the dissolution behaviors in vitro and plasma pharmacokinetics in vivo. Moreover, molecular simulation was performed to better understand their binding site and mode.
Here, we suggest that random amorphous and spherical ordered self-assemblies allow for long action without new molecular entities generation or carriers employed. By manipulating supersaturation, the ordered aggregates were self-organized at high concentration of Zn(II) (>100 mM) in pH 5.5-6.0, which was the first time that spherical semi-crystals of rhIFN can act as a depot source for the sustained delivery of biologically active proteins. The secondary structure and biological potency of rhIFN were unchanged after aggregation. Compared with that of the native rhIFN, both self-assemblies exhibited slower absorption and extended elimination profiles after s.c. administration, which were characterized as 4.75 ± 0.82 h and 10.58 ± 1.86 h of terminal half-life for random amorphous and spherical ordered self-assemblies, respectively.
The work described here demonstrates the possibility of self-assemblies of biomacromolecules for controllable release application of therapeutic proteins.
对 rhIFN 的无定形随机和球形晶体有序自组装体的持续释放性能进行比较研究。
采用批量结晶模式鉴定 rhIFN 自组装体。比较其理化特性,包括形态、XRD、FTIR、CD、生物效价、体外溶解行为和体内药代动力学。此外,还进行了分子模拟,以更好地了解其结合部位和方式。
在此,我们提出无定形随机和球形有序自组装体可以在不产生新的分子实体或使用载体的情况下实现长效作用。通过操纵过饱和度,在 pH5.5-6.0 下 Zn(II)浓度较高(>100mM)时,有序聚集体自组装,这是 rhIFN 的球形半晶体能首次作为生物活性蛋白持续释放的储库来源。rhIFN 的二级结构和生物效价在聚集后保持不变。与天然 rhIFN 相比,两种自组装体在皮下给药后吸收较慢,消除时间延长,其末端半衰期分别为 4.75±0.82h 和 10.58±1.86h。
这里描述的工作表明生物大分子自组装体用于治疗蛋白可控释放应用的可能性。